Arvinas News Releases http://ir.arvinas.com/ Arvinas News Releases en Arvinas Reports First Quarter Financial Results and Provides Corporate Update http://ir.arvinas.com/news-releases/news-release-details/arvinas-reports-first-quarter-financial-results-and-provides Initiated Patient Dosing in the First Phase 1 Clinical Trial with a Targeted PROTAC® Protein Degrader, ARV-110 NEW HAVEN, Conn. , May 08, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, Wed, 08 May 2019 07:00:00 -0400 Arvinas News Releases 7006 Arvinas Strengthens Management Team with Internal Appointments of Andy Crew, Ph.D. as Chief Technology Officer and Ian Taylor, Ph.D. as Chief Scientific Officer http://ir.arvinas.com/news-releases/news-release-details/arvinas-strengthens-management-team-internal-appointments-andy NEW HAVEN, Conn. , April 02, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, announced that two members of the senior leadership team were appointed to expanded roles at the company.  Andy Tue, 02 Apr 2019 07:00:00 -0400 Arvinas News Releases 6966 Arvinas Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update http://ir.arvinas.com/news-releases/news-release-details/arvinas-reports-fourth-quarter-and-full-year-2018-financial Recently Announced the Initiation of Patient Dosing in the First Phase 1 Clinical Trial with a Targeted PROTAC™ Protein Degrader ARV-110 NEW HAVEN, Conn. , March 26, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrade Tue, 26 Mar 2019 07:00:00 -0400 Arvinas News Releases 6941 Arvinas Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of PROTAC™ Protein Degrader, ARV-110 http://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-initiation-patient-dosing-first-phase-1 Study to Evaluate Safety and Tolerability of Androgen Receptor (AR)-targeted PROTAC™ Protein Degrader in Patients with Metastatic Castration-Resistant Prostate Cancer NEW HAVEN, Conn. , March 25, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class Mon, 25 Mar 2019 07:00:00 -0400 Arvinas News Releases 6936 Nature: Protein-slaying drugs could be the next blockbuster therapies http://ir.arvinas.com/news-releases/news-release-details/nature-protein-slaying-drugs-could-be-next-blockbuster-therapies Wed, 20 Mar 2019 08:00:00 -0400 Arvinas News Releases 6981 Nature Reviews Drug Discovery: First targeted protein degrader hits the clinic; New therapeutics that harness cellular machinery to degrade targets are entering clinical trials, led by a PROTAC anticancer candidate developed by Arvinas. http://ir.arvinas.com/news-releases/news-release-details/nature-reviews-drug-discovery-first-targeted-protein-degrader Wed, 06 Mar 2019 18:00:00 -0500 Arvinas News Releases 6926 Arvinas Announces Poster Presentation at ASCO 2019 Genitourinary Cancers Symposium http://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-poster-presentation-asco-2019-genitourinary Company to Highlight ARV-110 PROTAC™ Protein Degrader for the Treatment of Prostate Cancer NEW HAVEN, Conn. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that it will present a Thu, 07 Feb 2019 16:30:00 -0500 Arvinas News Releases 6881 Arvinas Receives Authorization to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer http://ir.arvinas.com/news-releases/news-release-details/arvinas-receives-authorization-proceed-its-ind-application Expects Enrollment of Phase 1 Trial to Begin in the First Quarter of 2019 NEW HAVEN, Conn. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the U.S. Fri, 04 Jan 2019 17:00:00 -0500 Arvinas News Releases 6866 Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS) http://ir.arvinas.com/news-releases/news-release-details/arvinas-presents-preclinical-data-protein-degrader-arv-471-2018 ARV-471 Degraded Estrogen Receptor and Provided Improved Anti-Tumor Activity When Compared to SOC, Both as a Monotherapy and in Combination NEW HAVEN, Conn. , Dec. 07, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted Fri, 07 Dec 2018 19:00:00 -0500 Arvinas News Releases 6861 Arvinas To Present at the 30th Annual Piper Jaffray Healthcare Conference http://ir.arvinas.com/news-releases/news-release-details/arvinas-present-30th-annual-piper-jaffray-healthcare-conference NEW HAVEN, Conn. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that John G. Houston , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 30th Tue, 20 Nov 2018 06:00:00 -0500 Arvinas News Releases 6846